Value-based pricing will focus primarily on new medicines. It is possible that a. small number of existing drugs, such as some cancer drugs previously considered but not recommended by the National Institute for Health and Care Excellence (NICE), could be assessed under value-based pricing. However, it is not our intention under value-based pricing to routinely reassess treatments already appraised by NICE.